147 related articles for article (PubMed ID: 31770215)
1. Prognostic significance of TRIM59 for cancer patient survival: A systematic review and meta-analysis.
Wang M; Chao C; Luo G; Wang B; Zhan X; Di D; Qian Y; Zhang X
Medicine (Baltimore); 2019 Nov; 98(48):e18024. PubMed ID: 31770215
[TBL] [Abstract][Full Text] [Related]
2. TRIM59: A potential diagnostic and prognostic biomarker in human tumors.
Jin Z; Liu L; Yu Y; Li D; Zhu X; Yan D; Zhu Z
PLoS One; 2021; 16(9):e0257445. PubMed ID: 34534244
[TBL] [Abstract][Full Text] [Related]
3. TRIM59 Is a Novel Marker of Poor Prognosis and Promotes Malignant Progression of Ovarian Cancer by Inducing Annexin A2 Expression.
Wang Y; Zhou Z; Wang X; Zhang X; Chen Y; Bai J; Di W
Int J Biol Sci; 2018; 14(14):2073-2082. PubMed ID: 30585270
[TBL] [Abstract][Full Text] [Related]
4. Potential value of tripartite motif-containing 59 as a biomarker for predicting the prognosis of patients with lung cancer: A protocol for systematic review and meta-analysis.
Guo J; Min K; Deng L
Medicine (Baltimore); 2021 Aug; 100(32):e26868. PubMed ID: 34397900
[TBL] [Abstract][Full Text] [Related]
5. [Expression of TRIM59 in Non-small Cell Lung Cancer and Its Correlation with Prognosis].
Tian H; Zhang D; Xu R; Qin Y; Lan Y; Jiao W; Han Y
Zhongguo Fei Ai Za Zhi; 2020 Jan; 23(1):21-28. PubMed ID: 31948534
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of Tripartite-59 (TRIM59) Inhibits Cellular Proliferation and Migration in Human Cervical Cancer Cells.
Aierken G; Seyiti A; Alifu M; Kuerban G
Oncol Res; 2017 Mar; 25(3):381-388. PubMed ID: 27662486
[TBL] [Abstract][Full Text] [Related]
7. The role of TRIM59 in immunity and immune-related diseases.
Jin Z; Chen T; Zhu Z; Xu B; Yan D
Int Rev Immunol; 2024; 43(1):33-40. PubMed ID: 35975813
[TBL] [Abstract][Full Text] [Related]
8. TRIM59 promotes breast cancer motility by suppressing p62-selective autophagic degradation of PDCD10.
Tan P; Ye Y; He L; Xie J; Jing J; Ma G; Pan H; Han L; Han W; Zhou Y
PLoS Biol; 2018 Nov; 16(11):e3000051. PubMed ID: 30408026
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of tripartite motif 59 and its diagnostic utility in benign bowel diseases and colorectal cancer.
Dahpy MA; Salama RHM; Kamal AA; El-Deek HE; AbdelMotaleb AA; Abd-El-Rehim AS; Hassan EA; Alsanory AA; Saad MM; Ali M
J Biochem Mol Toxicol; 2022 Jul; 36(7):e23065. PubMed ID: 35377964
[TBL] [Abstract][Full Text] [Related]
10. TRIM59 facilitates the proliferation of colorectal cancer and promotes metastasis via the PI3K/AKT pathway.
Sun Y; Ji B; Feng Y; Zhang Y; Ji D; Zhu C; Wang S; Zhang C; Zhang D; Sun Y
Oncol Rep; 2017 Jul; 38(1):43-52. PubMed ID: 28534983
[TBL] [Abstract][Full Text] [Related]
11. Association of the TRIM family protein with survival outcomes and clinicopathological features in colorectal cancer: a systematic review and meta-analysis.
Wu Y; Chen C; Hua X; Zhao C; Min H
BMC Cancer; 2024 Apr; 24(1):537. PubMed ID: 38678238
[TBL] [Abstract][Full Text] [Related]
12. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
Gene; 2019 May; 698():50-60. PubMed ID: 30822475
[TBL] [Abstract][Full Text] [Related]
13. TRIM59 promotes tumor growth in hepatocellular carcinoma and regulates the cell cycle by degradation of protein phosphatase 1B.
Ying H; Ji L; Xu Z; Fan X; Tong Y; Liu H; Zhao J; Cai X
Cancer Lett; 2020 Mar; 473():13-24. PubMed ID: 31875525
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive profiling of the TRIpartite motif family to identify pivot genes in hepatocellular carcinoma.
Wu L; Yin X; Jiang K; Yin J; Yu H; Yang L; Ma C; Yan S
Cancer Med; 2022 Apr; 11(7):1712-1731. PubMed ID: 35142083
[TBL] [Abstract][Full Text] [Related]
15. TRIM59 predicts poor prognosis and promotes pancreatic cancer progression via the PI3K/AKT/mTOR-glycolysis signaling axis.
Li R; Weng L; Liu B; Zhu L; Zhang X; Tian G; Hu L; Li Q; Jiang S; Shang M
J Cell Biochem; 2020 Feb; 121(2):1986-1997. PubMed ID: 31693252
[TBL] [Abstract][Full Text] [Related]
16. The role of Tripartite motif containing 59 (TRIM59) in the proliferation and prognosis of intrahepatic cholangiocarcinoma.
Zhang JN; Ding DY; Yang SY; Tao QF; Yang Y; Zhou WP
Pathol Res Pract; 2022 Aug; 236():153989. PubMed ID: 35753134
[TBL] [Abstract][Full Text] [Related]
17. TRIM59 as a novel molecular biomarker to predict the prognosis of patients with NSCLC.
Lou M; Gao Z; Zhu T; Mao X; Wang Y; Yuan K; Tong J
Oncol Lett; 2020 Feb; 19(2):1400-1408. PubMed ID: 31966070
[TBL] [Abstract][Full Text] [Related]
18. TRIM59 is up-regulated in gastric tumors, promoting ubiquitination and degradation of p53.
Zhou Z; Ji Z; Wang Y; Li J; Cao H; Zhu HH; Gao WQ
Gastroenterology; 2014 Nov; 147(5):1043-54. PubMed ID: 25046164
[TBL] [Abstract][Full Text] [Related]
19. Expression of tripartite motif-containing 44 and its prognostic and clinicopathological value in human malignancies:a meta-analysis.
Xiao G; Yang Q; Bao Z; Mao H; Zhang Y; Lin S
BMC Cancer; 2020 Jun; 20(1):525. PubMed ID: 32503466
[TBL] [Abstract][Full Text] [Related]
20. CDK5-dependent phosphorylation and nuclear translocation of TRIM59 promotes macroH2A1 ubiquitination and tumorigenicity.
Sang Y; Li Y; Zhang Y; Alvarez AA; Yu B; Zhang W; Hu B; Cheng SY; Feng H
Nat Commun; 2019 Sep; 10(1):4013. PubMed ID: 31488827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
